Furthermore, a study on pancreatic cancer patients who received PD-1 inhibitor-based therapies showed that a lower neutrophil-to-lymphocyte ratio predicted better tumor response [537]. This evidence concerns the gene PDCD1 and pancreatic neoplasm.